PubMed Central , Accessed 23 Apr
ven om glukagon ofta nmns tillsammans med GLP-1 har det en annan roll i energiregleringen
Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
Remember that nutritional supplements are not approved by the Food and Drug Administration (FDA), so do your due diligence before purchasing such products
What investors should track next: three questions HIMS must answer Going forward, HIMS needs to prove that: It can scale weight management in a compliant way It can maintain gross margin and growth under tighter regulation After GLP1-driven volatility fades, its subscription base can still compound over time Five metrics to watch in coming quarters Net subscriber adds + ARPU (average revenue per user): the hard indicators of quantity and quality of platform growth
Extending the findings from the UK cohort study, additional real-world data derived from the Taiwan National Health Insurance Databasewhich encompasses Asian populations characterized by lower gallstone prevalence, low-fat and high-fiber dietary patterns, and lower body mass indexalso documented an elevated risk of biliary-related diseases linked to GLP-1 RAs compared with SGLT-2 inhibitors [36]
